Latent tuberculosis: Is there a role for thioridazine?

Recent Patents on Anti-Infective Drug Discovery

Volumn 6, Issue 2, 2011, Pages 139-146

  Sohaskey, Charles ^a  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

Author keywords

Dormancy; Latent tuberculosis; MDR; Mycobacteria; Respiration; Thioridazine. XDR

Indexed keywords

PHENOTHIAZINE DERIVATIVE; THIORIDAZINE;

AGRANULOCYTOSIS; ARTICLE; BACTERIAL STRAIN; DISEASE COURSE; DISEASE MODEL; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHOTOTOXICITY; PRIORITY JOURNAL; QT PROLONGATION; RETROGRADE EJACULATION; SEDATION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PATENTS AS TOPIC; THIORIDAZINE; TREATMENT OUTCOME;

EID: 79959929330     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489111796064551     Document Type: Article

References (96)

1. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science 2010; 328: 856-61.
2. Lin PL, Flynn JL. Understanding latent tuberculosis: A moving target. J Immun 2010; 185: 15-22.
3. Ehlers SL. Dynamic or minimally recrudescent? on the elusive nature and location of the mycobacterium responsible for latent tuberculosis. Infection 2009.
4. Russell DG, Barry CEI, Flynn JL. Tuberculosis: What we don't know can, and does, hurt us. Science 2010; 328: 852-6.
5. Wayne LG, Sohaskey CD. Nonreplicating persistence of Mycobacterium tuberculosis. Ann Rev Microbiol 2001; 55: 139-63.
6. Voskuil MI, Schnappinger D, Harrell MI, Visconti KC, Dolganov GM, Sherman DR, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis persistence program. J Exp Med 2003; 198(5): 705-13.
7. Kumar A, Toledo JC, Patel RP, Lancaster JRJ, Steyn AJC. Mycobacterium tuberculosis DosS is a redox sensor and DosT is a hypoxia sensor. Proc Natl Acad Sci USA 2007; 104(28): 11568-73.
8. Wayne LG. The bacteriology of resected tuberculous pulmonary lesions. II. Observations on bacilli which are stainable but which cannot be cultured. Am Rev Resp Dis 1960; 82(3): 370-7.
9. Wayne LG, Salkin D. The Bacteriology of resected tuberculous pulmonary lesions. Amer Rev Tuber Pulm Dis 1956; 74(3): 376-87.
10. Opie EAJ. Tubercle bacilli in latent tuberculous lesions and in lung tissue without tuberculous lesions. Arch Pathol Lab Med 1927; 4: 1-21.
11. Griffith AS. Types of Tubercle bacilli in human tuberculosis. J Pathol Bacteriol 1929; 32: 813-40.
12. Feldman WH, Baggenstoss AH. The occurrence of virulent Tubercle bacilli in presumably non-tuberculous lung tissue. Amer J Pathol 1939; 15(5): 501-15.
13. Barry CEI, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, et al. The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7: 845-55.
14. Canetti G. The Tubercle bacillus in the pulmonary lesion of man. New York: Springer Publishing Com. Inc., 1955.
15. Hernández-Pando R, Jeyanathan M, Mengistu G, Aguilar D, Orozco H, Harboe M, et al. Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 2000; 356: 2133-7.
16. Neyrolles O, Hernández-Pando R, Pietri-Rouxel F, Fornès P, Tailleux L, Payàn JAB, et al. Is adipose tissue a place for Mycobacterium tuberculosis persistence. PLOS One 2006; 1(1): 1-9.
17. Boshoff HIM, Barry CEI. Tuberculosis - metabolism and respiration in the absence of growth. Nat Rev 2005; 3: 70-80.
18. Chao MC, Rubin EJ. Letting Sleeping dos Lie: Does dormancy play a role in tuberculosis. Ann Rev Microbiol 2010; 64: 293-311.
19. Gill WP, Harik NS, Whiddon MR, Liao RP, Mittler JE, Sherman DR. A replication clock for Mycobacterium tuberculosis. Nat Med 2009; 15(2): 211-4.
20. Shi L, Sohaskey CD, Pfeiffer C, Parks M, McFadden J, North RJ, et al. Carbon flux rerouting during Mycobacterium tuberculosis growth arrest. Mol Microbiol 2010; 78(5): 1199-215.
21. Shi L, Sohaskey CD, Kana BD, Dawes S, North RJ, Mizrahi V, et al. Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc Natl Acad Sci USA 2005; 102(43): 15529-34.
22. Shi L, Jung Y-J, Tyagi S, Gennaro ML, North R. Expression of Th1-mediated immunity in mouse lungs induces a Mycobacterium tuberculosis transcription pattern characteristic of nonreplicating persistence. Proc Natl Acad Sci USA 2003; 100(1): 241-6.
23. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, Monahan IM, et al. Transcriptional Adaptation of Mycobacterium tuberculosis within macrophages: Insights into the phagosomal environment. J Exp Med 2003; 198(5): 693-704.
24. Kana BD, Weinstein EA, Avarbock D, Dawes SS, Rubin H, Mizrahi V. Characterization of the cydAB-Encoded Cytochrome bd Oxidase from Mycobacterium smegmatis. J Bacteriol 2001; 183(24): 7076-86.
25. Sohaskey CD, Wayne LG. Role of narK2X and narGHJI in hypoxic upregulation of nitrate reduction by Mycobacterium tuberculosis. J Bacteriol 2003; 185(24): 7247-56.
26. Sohaskey CD. Regulation of nitrate reductase activity in Mycobacterium tuberculosis by oxygen and nitric oxide. Microbiol 2005; 151(11): 3803-10.
27. McCune RMJ, McDermott W, Tompsett R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956; 104(5): 763-802.
28. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a phenotypic switch. Science 2004; 305(5690): 1622-5.
29. Haapanen JH, Kass I, Gensini G, Middlebrook G. Studies on the Gaseous Content of Tuberculous Cavities. Amer Rev Resp Dis 1959; 80: 1-5.
30. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, et al. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 2008; 76(6): 2332-40.
31. Tsai MC, Chakravarty S, Zhu G, Xu J, Tanaka K, Koch C, et al. Characterization of the tuberculous granuloma in murine and human lungs: Cellular composition and relative tissue oxygen tension. Cell Microbiol 2006; 8(2): 218-32.
32. Wayne LG, Lin K-Y. Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions. Infect Immun 1982; 37(3): 1042-9.
33. Wayne LG, Hayes LG. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun 1996; 64(6): 2062-9.
34. Boshoff HIM, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CEI. The transcriptional responses of Mycobacterium tuberculosis to Inhibitors of Metabolism. J Biol Chem 2004; 279(38): 40174-84.
35. Muttucumaru DG, Roberts G, Hinds J, Stabler RA, Parish T. Gene expression profile of Mycobacterium tuberculosis in a nonreplicating state. Tuberculosis 2004; 84: 239-46.
36. Sohaskey CD. Nitrate enhances the survival of Mycobacterium tuberculosis during inhibition of respiration. J Bacteriol 2008; 190(8): 2981-86.
37. Rustad TR, Harrell MI, Liao R, Sherman DR. The enduring hypoxic response of Mycobacterium tuberculosis. PLOS One 2008; 3(1): 1-8.
38. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, Schoolnik GK. Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding [1]-crystallin. Proc Natl Acad Sci USA 2001; 98(13): 7534-9.
39. Park H-D, Guinn KM, Harrell MI, Liao R, Voskuil M, Tompa M, et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of M. tuberculosis. Mol Microbiol 2003; 48(3): 833-43.
40. Florczyk MA, McCue LA, Purkayastha A, Currenti E, Wolin MJ, McDonough KA. A family of acr-Coregulated Mycobacterium tuberculosis genes shares a common DNA motif and requires Rv3133c (dosR or devR) for Expression. Infect Immun 2003; 71(9): 5332-43.
41. Voskuil MI, Schnappinger D, Harrell MI, Visconti KC, Dolganov GM, Sherman DR, et al. Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis persistence program. J Exp Med 2002; 198(5): 705-13.
42. Boon C, Dick T. Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J Bacteriol 2002; 184(24): 6760-7.
43. Flynn JL, Scanga CA, Tanaka KE, Chan J. Effects of aminoguanidine on latent murine tuberculosis. J Immun 1998; 160: 1796-803.
44. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci USA 1997; 94: 5243-8.
45. Nathan C. Inducible nitric oxide synthase in the tuberculous human lung. Amer J Resp Crit Care Med 2002; 166: 130-1.
46. Chan ED, Chan J, Schluger NW. What is the role of nitric oxide in murine and human host defense against tuberculosis? Am J Respir Cell Mol Biol 2001; 25: 606-12.
47. Converse PJ, Karakousis PC, Klinkenberg LG, Kesavan AK, Ly LH, Allen SS, et al. Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun 2010; 77(3): 1230-7.
48. Flores-Valdez, M.A., Schoolnik, G.K., Klein, M., Sadoff, J., Hone, D. BCG vaccine strains protecting against the establishment of latent Mycobacterium tuberculosis infection. US2008083301 (2008).
49. Hampshire T, Soneji S, Bacon J, James BW, Hinds J, Laing K, et al. Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: A model for persistent organisms? Tuberculosis 2004; 84: 228-38.
50. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncap K. Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 2002; 43(3): 717-31.
51. Parish T. Starvation survival response of Mycobacterium tuberculosis. J Bacteriol 2003; 185(22): 6702-6.
52. Rifat D, Bishai WR, Karakousis PC. Phosphate depletion: A novel trigger for Mycobacterium tuberculosis persistence. J Infect Dis 2009; 200(7): 1126-35.
53. Deb C, Lee C-M, Dubey VS, Daneil J, Abomoelak B, Sirakova TD, et al. A Novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drugtolerant, dormant pathogen. PLOS One 2009; 4(6): 1-15.
54. Kim S-Y, Lee B-S, Shin SJ, Kim H-J, Park J-K. Differentially expressed genes in Mycobacterium tuberculosis H37Rv under mild acidic and hypoxic conditions. J Med Microbiol 2008; 57: 1473-80.
55. Kumar A, Deshane JS, Crossman DK, Bolisetty S, Yan B-S, Kramnik I, et al. Heme oxygenase-1-derived carbon monoxide induces the Mycobacterium tuberculosis dormancy regulon. J Biol Chem 2008; 283(26): 18032-9.
56. Weinstein EA, Yano T, Li L-S, Avarbock D, Avarbock A, Helm D, et al. Inhibitors of type II NADH: Menaquinone oxidoreductase represent a class of antitubercular drugs. Proc Natl Acad Sci USA 2005; 102(12): 4548-53.
57. Yaho T, Li L-S, Weinstein E, Teh J-S, Rubin H. Steady-state Kinetics and Inhibitory Action of Antitubercular Phenothiazines on Mycobacterium tuberculosis Type-II NADH-Menaquinone Oxidoreductase (NDH-2). J Biol Chem 2006; 281(17): 11456-63.
58. Rao SPS, Alonso S, Rand L, Dick T, Pethe K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2008; 105(33): 11945-50.
59. Bald D, Koul A. Respiratory ATP synthesis: The new generation of mycobacterial drug targets? FEMS Microbiol Lett 2010; 308(1): 1-7.
60. 2+ dependence and inhibitory effects of trifluoperazine on plasma membrane ATPase of Thermoactinomyces vulgaris. Curr Microbiol 2004; 49(1): 28-31.
61. Fry IJ, Villa L, Kuehn GD, Hageman JH. Calmodulin-like protein from Bacillus subtilis. Biochem Biophys Res Commun 1986; 134(1): 212-7.
62. Dutta NK, Mehra S, Kaushal D. A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine. PLOS One 2010; 5(4): 1-10.
63. Liz XZ, Nikaido H. Efflux-mediated drug resistance in bacteria: an update. Drugs 2009; 69(12): 1555-623.
64. Rodrigues L, Wagner D, Viveiros M, Sampaio D, Couto I, Vavra M, et al. Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis. J Antimicro Chem 2008; 61(5): 1076-82.
65. Kristiansen MM, Leandro C, Ordway D, Martins M, Viveiros M, Pacheco T, et al. Thioridazine reduces resistance of methicillinresistant Staphylococcus aureus by inhibiting a reserpine-sensitive efflux pump. In vivo 2006; 20(3): 361-6.
66. Viveiros M, Portugal I, Bettencourt R, Victor TC, Jordaan AM, Leandro C, et al. Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicro Agents Chemo 2002; 46(9): 2804-10.
67. Molnar J, Hever A, Fakla I, Fischer J, Ocsovski I, Aszalos A. Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells. Anticancer Res 1997; 17(1A): 481-6.
68. Viveiros M, Amaral L. Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Inter J Antimicro Agents 2001; 17: 225-8.
69. Amaral L, Kristiansen JE, Abebe LS, Millett W. Inhibition of the respiration of multi-drug resistant clinical isolated of Mycobacterium tuberculosis by thioridazine: Potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicro Chemo 1996; 38: 1049-53.
70. van Ingen J, van der Laan T, Amaral L, Dekhuijzen R, Boeree MJ, van Soolingen D. In vitro activity of thioridazine against mycobacteria. Inter J Antimicro Agents 2009; 34: 190-191.
71. Ordway D, Viveiros M, Leandro C, Betterncourt R, Almeida J, Martins M, et al. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicro Agents Chemotherap 2003; 47(3): 917-22.
72. Bettencourt MV, Bosne-David S, Amaral L. Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Inter J Antimicro Agents 2000; 16: 69-71.
73. Amaral L, Kristiansen JE, Viveiros M, Atouguia J. Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: A review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J Antimicro Chemo 2001; 47: 505-11.
74. Amaral L, Martins M, Viveiros M, Molnar J, Kristiansen JE. Promising therapy of XDR-TB/MDR-TB with thioridazine an inhibitor of bacterial efflux pumps. Curr Drug Targ 2008; 9: 816-19.
75. Crowle AJ, Doubas GS, May MH. Chlorpromazine: A drug potentially useful for treating mycobacterial infections. Chemotherapy 1992; 38(6): 410-19.
76. + transport enhance intracellular killing of M. tuberculosis by nonkilling macrophages. In vivo 2008; 22(1): 69-75.
77. Forrest FM, Forrest IS, Roizin L. Clinical, biochemical and post mortem studies on a patient treated with chlorpromazine. Agressologie 1963; 4: 259-65.
78. Martins M, Viveiros M, Kristiansen JE, Molnar J, Amaral L. The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In vivo 2007; 21: 771-6.
79. van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, et al. The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLOS One 2010; 5(9): 1-6.
80. Menzles D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Resp Crit Care Med 2004; 170(4): 445-9.
81. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International union against tuberculosis committee on prophylaxis. Bull World Health Organ 1982; 60(4): 555-64.
82. Xie Z, Siddiqi N, Rubin EJ. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicro Agents Chemotherap 2005; 49(11): 4778-80.
83. Gengenbacher M, Rao SPS, Pethe K, Dick T. Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability. Microbiology 2010; 156: 81-7.
84. Starck J, Kalenius G, Marklund B-I, Andersson DI, Akerlund T. Comparative proteome analysis of Mycobacterium tuberculosis grown under aerobic and anaerobic conditions. Microbiology 2004; 150: 3821-9.
85. Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008; 283(37): 25273-80.
86. Tan MP, Sequeira P, Lin WW, Phong WY, Cliff P, Ng SH, et al. Nitrate respiration protects hypoxic Mycobacterium tuberculosis against acid- and reactive nitrogen species stresses. PLOS One 2010; 5(10): 1-8.
87. Keshavjee S, Farmer PE. Picking up the pace - scale-up of MDR tuberculosis treatment programs. New Engl J Med 2010; 363(19): 1781-4.
88. Funding options paper - thirteenth board meeting. The global fund to fight AIDS. Tuberculosis Malaria, Geneva 2010; 10 Apr 27.
89. Fred D, Desai M, Song R, Bamrah S, Pavlin BI, Heetderks A, et al. Multi-drug resistant tuberculosis in Chuuk State, Federated States of Micronesia, 2008-2009. Pacific Health Dialog 2010; 16(1): 123-7.
90. Kaminska M. Role of chlorpromazine in the treatment of pulmonary tuberculosis in psychiatric patients. Folia Medica Cracoviensia 1967; 9: 115-43.
91. Abbate E, Vescovo M, Natiello M, Cufré M, García A, Ambroggi M, et al. Tuberculosis extensamente resistente (XDR-TB) en Argentina: Aspectos destacables epidemiológicos, bacteriológicos, terapéuticos y evolutivos. Rev Argen Med Respir 2010; 1: 19-25.
92. Martins M, Schelz Z, Martins A, Molnar J, Hajõs G, Riedl Z, et al. In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis. Inter J Antimicro Agents 2007; 29: 338-40.
93. Amaral L, Molnar J. Therapy of XDR TB with thioridazine a drug beyond patent protection but eligible for patent As New Use. Rec Pat Anti-Infect Drug Discov 2010; 5: 109-14.
94. Amaral L, Martins M, Viveiros M. Phenothiazines as anti-multidrug resistant tubercular agents. Infect Disorders - Drug Targets 2007; 7: 257-65.
95. Thanacoody HKR. Thioridazine: Resurrection as an antimicrobial agent. Brit J Clin Pharmac 2007; 64(5): 566-71.
96. Christensen, J.B., Hendricks, O., Kristiansen, J.E. Thioridazine and derivatives thereof for reversing anti-microbial drug-resistance. IB2004003730 (2004).